Form 4: Gossamer Bio Director Receives Stock Option Grant

Director Steven D. Nathan was granted 115,000 stock options as part of the Gossamer Bio, Inc. non-employee director compensation program.

Summary

• Director Steven D. Nathan received a grant of 115,000 stock options on June 4, 2026.
• The options have an exercise price of $0.178 per share.
• The options are set to expire on June 3, 2036.
• Vesting occurs on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, contingent on continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future dilution of existing shareholders upon the exercise of these options.

Risks

• Market volatility affecting the value of the underlying common stock.
• Dependence on continued board service for the vesting of the granted options.

Future Outlook

The options vest on the earlier of the first anniversary of the grant or the next annual meeting, assuming continued service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to incentivize board members and align their interests with long-term corporate performance.

Comparison to Industry Standards

• The grant follows standard industry practices for non-employee director compensation programs in mid-cap biotech firms.
• Vesting schedules tied to annual meetings or one-year anniversaries are consistent with typical governance benchmarks for public companies.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution if options are exercised.

Next Steps

• Vesting of options on the earlier of June 4, 2027, or the next annual meeting of stockholders.

Key Dates

Keywords

Gossamer Bio, GOSS, Form 4, Insider Trading, Stock Options, Director Compensation